VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$0.30 USD
-0.01 (-1.87%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.32 +0.02 (5.19%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, VYNE Therapeutics Inc. has a market cap of $7.90M, which represents its share price of $0.31 multiplied by its outstanding shares number of 25.47M. As a small-cap company, VYNE's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VYNE 0.30 -0.01(-1.87%)
Will VYNE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYNE
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
Other News for VYNE
VYNE forms 20 Day Moving Average Resistance on September 20
Hammer Candlestick appears for VYNE after 1.94% move
NR7 appears for VYNE after 0.62% move
VYNE forms 20 Day Moving Average Resistance on September 16
VYNE forms Bollinger Band Squeeze on September 15